Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Ticker SymbolABVX
CompanyAbivax SA
CEOde Garidel (Marc)
Websitehttps://www.abivax.com/
FAQs
What is the current price of Abivax SA (ABVX)?
The current price of Abivax SA (ABVX) is 145.310.
What is the symbol of Abivax SA?
The ticker symbol of Abivax SA is ABVX.
What is the 52-week high of Abivax SA?
The 52-week high of Abivax SA is 142.490.
What is the 52-week low of Abivax SA?
The 52-week low of Abivax SA is 4.770.
What is the market capitalization of Abivax SA?
The market capitalization of Abivax SA is --.
What is the net income of Abivax SA?
The net income of Abivax SA is --.
Is Abivax SA (ABVX) currently rated as Buy, Hold, or Sell?
According to analysts, Abivax SA (ABVX) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Abivax SA (ABVX)?
The Earnings Per Share (EPS TTM) of Abivax SA (ABVX) is --.